67
Participants
Start Date
May 20, 2014
Primary Completion Date
April 30, 2019
Study Completion Date
April 30, 2019
MEDI4736 Evaluate MEDI4736 in MDS
MEDI4736 will be administered by IV infusion
VIDAZA
VIDAZA will be administered subcutaneously as described on the package insert VIDAZA will be administered in combination with MEDI4736 upon progression from MEDI4736 monotherapy
tremelimumab
tremelimumab will be administered by IV infusion
Research Site, Dresden
Research Site, New York
Research Site, New York
Research Site, Baltimore
Research Site, Greenville
Research Site, Atlanta
Research Site, Tampa
Research Site, Detroit
Research Site, Milwaukee
Research Site, Rochester
Research Site, Chicago
Research Site, Paris
Research Site, Houston
Research Site, San Antonio
Research Site, Scottsdale
Research Site, Los Angeles
Research Site, New Haven
Research Site, Boston
Research Site, Brighton
Research Site, London
Research Site, Manchester
Lead Sponsor
MedImmune LLC
INDUSTRY